Technology

Robert Allen, Ph.D., Chief Scientific Officer, outlines how the company's Invymab platform uses viral surveillance and predictive modeling to design monoclonal antibodies against likely future variants rather than current strains.

AI can generate words that sound like empathy, but it cannot offer the understanding that a real person can.

Ken Banta and Craig Tooman on why the best leaders win by asking better questions — not just chasing more data — and what that means for drug development, funding and AI in the years ahead.

Insilico Medicine and Bora Pharmaceuticals entered a strategic alliance to pair Insilico's AI drug discovery platform with Bora's development and manufacturing infrastructure.

Insilico Medicine has deepened its partnership with China Medical System Holdings with a second CNS-focused collaboration in three months, pairing Insilico's PandaOmics-identified mechanism with CMS's clinical and commercial infrastructure in a deal worth up to $177 million in milestones.

The two companies will work together to advance the development of small molecule discovery at the research center.

Sanofi Chief Digital Officer Emmanuel Frenehard on scaling AI across a Big Pharma global enterprise and why a strategy of concentrated AI bets — not scattered pilots — can better drive real transformation without losing sight of governance, culture or patients.

Aprecia’s president and COO discusses the impact 3D printing technology is having on drug development, along with the benefits and challenges of being a company that is 100-percent US-based for its manufacturing.

Insilico will use its AI platform for the drug development process, while SK handles the late-stage and commercialization processes.

Novavax’s EVP of corporate affairs and head of its Sweden division discusses new vaccine technologies, such as its adjuvant matrix technology, are bringing new players into the space.

With clinical trial data exploding to nearly 6 million datapoints, eClinical Solutions' CEO and Co-founder, Raj Indupuri makes the case for price transparency and a measurable ROI in clinical data technology.

The driving force behind Lilly’s Medicine Foundry on transforming the discovery-to-production handoff.

Special Guest Op-Ed: The time is now to elevate manufacturing and supply to a defining pillar of life sciences innovation.

AI-powered data analytics has evolved from a supporting function into the backbone of modern brand strategy and decision-making.

Chai Discovery has licensed its generative AI drug discovery platform to Pfizer, giving the company early access to its next-generation Chai-3 model and a custom model trained on Pfizer's own data.

Alnylam Pharmaceuticals has partnered with Inceptive to apply generative AI to siRNA design, pairing Inceptive's biology-trained models with Alnylam's two decades of proprietary RNAi data to accelerate candidate discovery.

Prescryptive Health’s chief commercial officer discusses the results of a market access survey that asked industry executives about DTC models, affordability, and patient access.

Harpreet Singh, former FDA Oncology Division Director and current chief medical officer at Precision for Medicine notes how evolving FDA review standards, expedited approval programs, and emerging AI tools are reshaping the regulatory landscape for biopharma companies.

In today's Pharmaceutical Executive Daily, Reuters reports that lower-priced oral GLP-1 pills from Eli Lilly and Novo Nordisk are drawing patients away from compounded weight loss medications, Gilead Sciences' renews its five-year collaboration with WHO and Johnson and Johnson’s collaboration with the Department of Health Abu Dhabi, finally Partha Anbil argues that truly industrializing machine learning and AI in life sciences requires systems that are scientifically credible, clinically defensible, regulatorily traceable, and operationally sustained.

Life science organizations that will lead the next decade ar those that deploy systems that are scientifically credible, clinically defensible, regulatorily traceable, and operationally sustained.

New partnerships from Gilead Sciences and Johnson & Johnson highlight how healthcare companies are using collaborations to expand global disease initiatives and accelerate development of AI-enabled healthcare infrastructure.

Eli Lilly acquires Engage Biologics in up to $202 million deal to strengthen its genetic medicines portfolio with a non-viral DNA delivery platform designed to improve durability, tolerability, and re-dosing potential.

Bristol Myers Squibb and Incyte expand AI capabilities through major collaborations aimed at embedding agentic and molecular AI directly into drug discovery, development, and enterprise operations.

Regeneron and Parabilis Medicines partner to discover and develop antibody-Helicon conjugates, aiming to create a new class of therapies capable of targeting historically “undruggable” intracellular proteins.

Trialynx’s CEO discusses the benefits of using AI for trial design and how to find the AI companies doing the most promising work.